REGENESIS · MSCEXOS

The New Human Is Already Here.

"The question is whether your protocols are ready."

THE STANDARD

"In a market flooded with unverifiable
products from opaque sources,
regulatory clarity is not a differentiator.
It is the only thing that matters."

Most biologics distributed in the Americas today cannot answer a simple question: where, exactly, did they come from — and under what standard were they manufactured? MSCExos was built to answer that question with absolute certainty — for every product, every order, every patient.

Human hand — warm natural light
REGENERATIVE MEDICINE INFRASTRUCTURE

The Clinical Infrastructure Partner for the World's Most Demanding Practices.

MSCExos connects our clinically validated Placental MUSE Cells and US FDA-accredited BioXtek® exosomes to clinics worldwide leading this transformation. We are not a catalog. We are not a vendor. We are the operating system on which great regenerative medicine practices run their most differentiated programs.

0% Exosome purity
100B — 1T Particles per vial
0+ Therapeutic peptides
OUR MANUFACTURING PARTNERS

Two Platforms.
One Standard.

MSCExos brings together two of the most credentialed biological manufacturers available to the American market — BioXtek®, a US FDA-accredited innovator in exosome technology, and a leading US clinical-grade manufacturer of the world's most clinically validated Placental MUSE Cell therapy.

Placental MUSE Cells — US Clinical Grade
UNITED STATES

US-Sourced
Placental MUSE Cells

Our manufacturing partner produces cryopreserved Placental MUSE Cells under ISO 6 cleanroom conditions with ISO 5 air quality, isolated from human amnion and chorion membranes. MUSE cells are the only stem cell type combining immune evasion (HLA-G expression), damage-seeking migration (S1PR2/CXCR4 receptors), and true pluripotent capacity — three properties no other stem cell simultaneously possesses. Backed by 15+ years of research and six completed human clinical trials with a 100% safety record, they represent the most clinically validated cellular therapy available to the American market.

  • ISO 6 cleanroom · ISO 5 air quality, Terra Universal certified
  • SSEA3+ purity >90% (93% confirmed by flow cytometry, Lot #1012)
  • Post-thaw viability 94–96% · 30M cells per vial · Passage 4
  • DMSO-free XT-Thrive cryoprotectant (FDA Master File)
  • Sterility & endotoxin testing at Dana-Farber Cancer Institute
  • 6 human clinical trials · 100% success rate · Zero adverse events
Cryogenic storage tanks — cord blood preservation
UNITED STATES

BioXJel+ —
BioXtek® Source

Our US domestic biologic line, BioXJel+, is manufactured by BioXtek®, a pioneering regenerative therapeutics company harnessing the power of human placental birth tissues. Operating in full compliance with cGMP and cGTP standards, BioXtek is AATB-accredited and FDA-registered, with active IRB-approved clinical trials and an ongoing IND application pathway with the US FDA. Their proprietary BioPür Process® concentrates and preserves the full bioactive payload — exosomes, growth factors, peptides, cytokines, miRNA, and ECM components — from qualified single-birth placental donors, ensuring pharmaceutical-grade consistency and safety in every batch.

  • AATB-accredited, cGMP & cGTP compliant facility
  • Proprietary BioPür Process® platform technology
  • Sourced from qualified single-birth placental donors
  • Averaging 350B protein particles per concentrate
  • Bioactive cargo: exosomes, miRNA, growth factors, peptides, hyaluronic acid & ECM/collagens
  • FDA-registered topical cosmetic + active IND pathway for injectable therapeutics
  • US-compliant peptide therapeutics

Whether your clinic is in Miami, Mexico City, São Paulo, Bogotá, or Madrid — MSCExos delivers compliance-grade biologics appropriate to your regulatory environment.

THE PORTFOLIO

Not a Catalog.
A Curated Platform.

Three product families. Each selected because it meets a standard most of the market cannot match.

Luminous translucent sphere — MUSE-enriched exosome
01

MUSE-Enriched Exosomes

US FDA-Accredited · BioXtek®

Derived from Wharton's Jelly MSC, enriched with MUSE cells — a rare pluripotent subpopulation with up to 10x the potency of conventional MSCs. 99% purity. 100 billion particles per vial. Lyophilized for stable cold-chain transport and reconstitution at the point of care.

99% purity 100B particles/vial MUSE-enriched Lyophilized
Backlit leaf vascular network — living systems, cellular pathways
02

Placental MUSE Cells

US-Sourced · Clinical Grade

Cryopreserved placental MUSE cells manufactured from amnion and chorion membranes, isolated under ISO 5 cleanroom conditions and vialed in DMSO-free XT-Thrive cryoprotectant. Post-thaw viability confirmed at 94–96% at Passage 4. SSEA3+ purity 93% by flow cytometry; CD73, CD90, and CD105 expression all above 99%. Sterility and endotoxin testing conducted at Dana-Farber Cancer Institute; mycoplasma clearance certified by Bionique Testing Laboratories.

94–96% post-thaw 30M cells/vial SSEA3+ 93% DMSO-free
Therapeutic Peptides — molecular chemistry
03

Therapeutic Peptides

US-Sourced, Clinically Curated

70+ specialized bioactive peptides across five therapeutic categories: immune modulation, tissue regeneration, mitochondrial function, hormonal balance, and performance optimization. US-sourced from compliant domestic manufacturers. Complete clinical protocols included with every order.

70+ compounds US-sourced 5 therapeutic categories Protocols included
THE DIFFERENTIATOR

The Infrastructure
No One Can Buy.

Compliance, education, scientific provenance, and curatorship of the new. These are not features. They are the foundation of every partnership MSCExos builds.

01 —

Compliance as the Luxury

Placental MUSE Cells — backed by six completed human clinical trials and 15+ years of peer-reviewed research — and US FDA-accredited BioXtek® exosomes establish a clinical evidence standard that compounding pharmacies and gray-market distributors cannot approach. This is not a feature. It is the foundation.

02 —

Not a Vendor. An Operating System.

Partner clinics receive clinical education libraries, peer-reviewed protocol documentation, co-marketing assets, and access to the Regenesis thought leadership platform. We build the practice around the product — not the other way around.

03 —

Peer-Reviewed. Clinically Associated.

MUSE cell technology is supported by six completed human clinical trials across stroke, ALS, spinal cord injury, cardiac recovery, and epidermolysis bullosa — including a double-blind placebo-controlled trial demonstrating 32% complete recovery in stroke patients versus 0% placebo. Partner clinics deploy this evidence as a clinical narrative that positions them with authority their patients can trust.

04 —

We Lead. We Don't Follow.

MSCExos identifies what the next five years of regenerative medicine will look like and gives partner clinics access today. Through Regenesis magazine, we are the editorial authority on what is next — not a catalog of what already exists.

FOR CLINICAL PARTNERS

Built for Clinics That
Compete on Excellence.

Luxury clinic consultation — precision medicine

MSCExos does not supply clinics. It transforms them.

Partner clinics gain access to our Placental MUSE Cells — the most clinically validated stem cell therapy in the world, with six completed human trials and zero serious adverse events — alongside BioXtek® exosomes for a complete regenerative medicine offering.

White-label clinical education materials for your own medical staff. Published peer-reviewed protocol documentation presented to your patients as part of an evidence-first care philosophy.

A distribution relationship structured for long-term alignment and regional exclusivity. Not transactional volume. Not a catalog. A partnership.

PARTNERSHIP TERMS
Minimum Order No minimum — first order
Cold Chain 72-hour validated transport
Clinical Support Dedicated onboarding + protocols
Co-Marketing REGENESIS + MSCExos Academy
Exclusivity Regional terms available
Begin the Conversation
CLINICAL SEGMENTS

Three Markets.
One Infrastructure.

01

Longevity & Precision Medicine

Protocol-driven practices focused on biological age reversal, healthspan optimization, and cellular regeneration. MSCExos provides the exosome and MUSE cell portfolio with the clinical evidence framework to match.

02

Integrative & Functional Medicine

Clinics treating chronic inflammatory conditions, neurological disorders, autoimmune dysfunction, and post-surgical recovery. Our product suite and peer-reviewed protocols support evidence-based cellular therapy programs.

03

Aesthetics & Regenerative MedSpa

Results-first practices offering skin rejuvenation, hair restoration, and post-procedure recovery. Exosomes deliver 100x more growth factors than PRP — with zero blood draw and a defensible quality story that elevates the clinic brand.

REGENESIS

The clinics that will define
the next decade of medicine
are already choosing their
infrastructure partners.

"The question is which side of that line you are on."

Contact Us Right Now

clinics@mscexos.com · +1 463.465.2224

The information provided is for educational purposes only and does not constitute medical advice. Regenerative biologic products and peptide therapies offered through MSCExos are not FDA-approved for the prevention, treatment, or cure of any disease or condition. Individual results may vary. All protocols are physician-supervised and administered under informed consent.